Leerink Partners analyst David Risinger has maintained their bullish stance on SNYNF stock, giving a Buy rating on September 6.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Risinger has given his Buy rating due to a combination of factors that reflect both the challenges and potential opportunities for Sanofi. Despite the amlitelimab Phase 3 trial results falling short of expectations compared to Dupixent’s performance, the treatment still met its primary and secondary endpoints, suggesting it could have a role in second-line settings. The novel mechanism of action and the convenience of quarterly dosing could provide a competitive edge in a crowded atopic dermatitis market.
Additionally, the safety profile of amlitelimab was favorable, with low rates of adverse events, which is a positive indicator for its future use. Risinger also notes the ongoing and upcoming trials for amlitelimab, which could potentially reveal more favorable data and enhance its market position. These factors, combined with Sanofi’s broader strategic initiatives and pipeline, contribute to the Buy rating, as they indicate potential for growth and value creation in the long term.
In another report released on September 6, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a €88.00 price target.